Skip to content

Study · Non-randomized trial · n = 28 · 2004

3 results

Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle.

Suh J, Lee E, Hwang S, Yoon S, Yoon BK, Bae D, Choi D

European journal of obstetrics, gynecology, and reproductive biology1 Jan 2004Cited by 1 (Europe PMC)

PMID14687742 (opens in a new tab)DOI10.1016/s0301-2115(03)00317-8 (opens in a new tab)PepBankPUB-14687742
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In IVF patients, serum estradiol, progesterone and leptin levels did not differ significantly among nafarelin dose groups.

    In plain wordsSerum hormone levels were similar among nafarelin dose groups in IVF patients.

    Peptide
    Nafarelin
    Outcome
    No significant changeSerum hormone levels
    Study

    n = 28

    Comparator
    Other nafarelin dose groups
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    No significant difference was noted in serum estradiol, progesterone, and leptin levels.
    1 context sentence
    Summary · context
    Twenty-eight IVF patients with normal ovarian function were divided into three groups: group I received GnRHa (nafarelin acetate/Synarel) intranasally at 200 microg daily, group II received 400 microg daily until hCG injection, and group III was given 400 microg daily before the initiation of ovaria…
  2. 02HumanNon-randomized trialEfficacy outcome

    In IVF patients, intrafollicular PAPP-A expression was higher with nafarelin 400 microg daily than 200 microg daily (P<0.05).

    In plain wordsThe higher nafarelin dose increased follicular PAPP-A expression compared with the lower dose.

    Peptide
    Nafarelin
    Outcome
    IncreaseIntrafollicular PAPP-A expression
    Study

    n: not reported in source

    Comparator
    200 microg daily
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 microg daily until hCG injection · intranasalAs given in this study (human).

    Source sentences

    Summary
    But intrafollicular PAPP-A expression was significantly higher in group II compared to other groups (P<0.05).
    1 context sentence
    Summary · context
    Twenty-eight IVF patients with normal ovarian function were divided into three groups: group I received GnRHa (nafarelin acetate/Synarel) intranasally at 200 microg daily, group II received 400 microg daily until hCG injection, and group III was given 400 microg daily before the initiation of ovaria…
  3. 03HumanNon-randomized trialEfficacy outcome

    In IVF patients, intrafollicular PAPP-A expression was higher with sustained nafarelin 400 microg daily than the decreasing-dose regimen (P<0.05).

    In plain wordsSustained higher-dose nafarelin increased follicular PAPP-A expression compared with the decreasing-dose regimen.

    Peptide
    Nafarelin
    Outcome
    IncreaseIntrafollicular PAPP-A expression
    Study

    n: not reported in source

    Comparator
    400 microg daily before ovarian stimulation, then 200 microg daily before hCG injection
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 microg daily until hCG injection · intranasalAs given in this study (human).

    Source sentences

    Summary
    But intrafollicular PAPP-A expression was significantly higher in group II compared to other groups (P<0.05).
    1 context sentence
    Summary · context
    Twenty-eight IVF patients with normal ovarian function were divided into three groups: group I received GnRHa (nafarelin acetate/Synarel) intranasally at 200 microg daily, group II received 400 microg daily until hCG injection, and group III was given 400 microg daily before the initiation of ovaria…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.